Schizophrenia for Primary Care Providers: How to Contribute to the Care of a Vulnerable Patient Population


      Patients with schizophrenia represent a vulnerable population with high medical needs that are often missed or undertreated. Primary care providers have the potential to reduce health disparities experienced by this population and make a substantial difference in the overall health of these patients. This review provides primary care providers with a general understanding of the psychiatric and medical issues specific to patients with schizophrenia and a clinically practical framework for engaging and assessing this vulnerable patient population and assisting them in achieving optimal health. Initial steps in this framework include conducting a focused medical evaluation of psychosis and connecting patients with untreated psychosis to psychiatric care as promptly as possible. Given the significant contribution of cardiovascular disease to morbidity and mortality in schizophrenia, a top priority of primary care for patients with schizophrenia should be cardiovascular disease prevention and treatment through regular risk factor screening, appropriate lifestyle interventions, and other indicated therapies.


      To read this article in full you will need to make a payment


        • McGrath J.
        • Saha S.
        • Chant D.
        • Welham J.
        Schizophrenia: a concise overview of incidence, prevalence, and mortality.
        Epidemiol Rev. 2008; 30: 67-76
        • Henry L.P.
        • Amminger G.P.
        • Harris M.G.
        • et al.
        The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission.
        J Clin Psychiatry. 2010; 71: 716-728
        • Viron M.J.
        • Stern T.A.
        The impact of serious mental illness on health and healthcare.
        Psychosomatics. 2010; 51: 458-465
        • Gold K.J.
        • Kilbourne A.M.
        • Valenstein M.
        Primary care of patients with serious mental illness: your chance to make a difference.
        J Fam Pract. 2008; 57: 515-525
        • Colton C.W.
        • Manderscheid R.W.
        Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.
        Prev Chronic Dis. 2006; 3: 1-14
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR.
        4th ed. American Psychiatric Association, Washington, DC2000
        • Freudenreich O.
        • Schulz S.C.
        • Goff D.C.
        Initial medical work-up of first-episode psychosis: a conceptual review.
        Early Interv Psychiatry. 2009; 3: 10-18
        • American Psychiatric Association
        Proposed draft revisions to DSM disorders and criteria.
        2011 (Accessed April 6, 2011)
        • Freudenreich O.
        Curr Psychiatr. 2009; 8: 74
        • Foussias G.
        • Remington G.
        Negative symptoms in schizophrenia: avolition and Occam's razor.
        Schizophr Bull. 2010; 36: 359-369
        • Palmer B.W.
        • Dawes S.E.
        • Heaton R.K.
        What do we know about neuropsychological aspects of schizophrenia?.
        Neuropsychol Rev. 2009; 19: 365-384
        • Peralta V.
        • Campos M.S.
        • De Jalon E.G.
        • Cuesta M.J.
        Motor behavior abnormalities in drug-naive patients with schizophrenia spectrum disorders.
        Mov Disord. 2010; 25: 1068-1076
        • Carlat D.J.
        The Psychiatric Interview: A Practical Guide.
        in: 2nd ed. Lippincott Williams & Wilkins, Philadelphia2005: 190-209
        • Brodkey A.C.
        • Van Zant K.
        • Sierles F.S.
        Educational objectives for a junior psychiatry clerkship: development and rationale.
        Acad Psychiatry. 1997; 21: 179-204
        • Bebbington P.E.
        • Nayani T.
        The psychosis screening questionnaire.
        Int J Methods Psychiatr Res. 1995; 5: 11-19
        • Salimi K.
        • Jarskog L.F.
        • Lieberman J.A.
        Antipsychotic drugs for first-episode schizophrenia: a comparative review.
        CNS Drugs. 2009; 23: 837-855
        • Stahl S.M.
        • Mignon L.
        • Meyer J.M.
        Which comes first: atypical antipsychotic treatment or cardiometabolic risk?.
        Acta Psychiatr Scand. 2009; 119: 171-179
        • Hasnain M.
        • Fredrickson S.K.
        • Vieweg W.V.
        • Pandurangi A.K.
        Metabolic syndrome associated with schizophrenia and atypical antipsychotics.
        Curr Diab Rep. 2010; 10: 209-216
        • ADA
        • APA
        • AACE
        • NAASO
        Consensus development conference on antipsychotic drugs and obesity and diabetes.
        Diabetes Care. 2004; 27: 596-601
        • Nussbaum A.
        • Stroup T.S.
        Paliperidone for schizophrenia.
        Cochrane Database Syst Rev. 2008; (CD006369)
        • Citrome L.
        Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
        Int J Clin Pract. 2009; 63: 1762-1784
        • Caccia S.
        • Pasina L.
        • Nobili A.
        New atypical antipsychotics for schizophrenia: iloperidone.
        Drug Des Devel Ther. 2010; 4: 33-48
        • Citrome L.
        Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.
        Clin Schizophr Relat Psychoses. 2011; 4: 251-257
        • Lieberman J.A.
        • Stroup T.S.
        • McEvoy J.P.
        • et al.
        Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
        N Engl J Med. 2005; 353: 1209-1223
        • Asenjo Lobos C.
        • Komossa K.
        • Rummel-Kluge C.
        • et al.
        Clozapine versus other atypical antipsychotics for schizophrenia.
        Cochrane Database Syst Rev. 2010; 11 (CD006633)
        • Correll C.U.
        Balancing efficacy and safety in treatment with antipsychotics.
        CNS Spectr. 2007; 12 (35): 12-20
        • Brown S.
        • Kim M.
        • Mitchell C.
        • Inskip H.
        Twenty-five year mortality of a community cohort with schizophrenia.
        Br J Psychiatry. 2010; 196: 116-121
        • Saha S.
        • Chant D.
        • McGrath J.
        A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?.
        Arch Gen Psychiatry. 2007; 64: 1123-1131
        • Harris E.C.
        • Barraclough B.
        Excess mortality of mental disorder.
        Br J Psychiatry. 1998; 173: 11-53
        • Palmer B.A.
        • Pankratz V.S.
        • Bostwick J.M.
        The lifetime risk of suicide in schizophrenia: a reexamination.
        Arch Gen Psychiatry. 2005; 62: 247-253
        • Luoma J.B.
        • Martin C.E.
        • Pearson J.L.
        Contact with mental health and primary care providers before suicide: a review of the evidence.
        Am J Psychiatry. 2002; 159: 909-916
        • Stovall J.
        • Domino F.J.
        Approaching the suicidal patient.
        Am Fam Physician. 2003; 68: 1814-1818
        • Osby U.
        • Correia N.
        • Brandt L.
        • Ekbom A.
        • Sparén P.
        Mortality and causes of death in schizophrenia in Stockholm county, Sweden.
        Schizophr Res. 2000; 45: 21-28
        • Laursen T.M.
        • Munk-Olsen T.
        • Agerbo E.
        • Gasse C.
        • Mortensen P.B.
        Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder.
        Arch Gen Psychiatry. 2009; 66: 713-720
        • McEvoy J.P.
        • Meyer J.M.
        • Goff D.C.
        • et al.
        Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
        Schizophr Res. 2005; 80: 19-32
        • Morden N.E.
        • Mistler L.A.
        • Weeks W.B.
        • Bartels S.J.
        Health care for patients with serious mental illness: family medicine's role.
        J Am Board Fam Med. 2009; 22: 187-195
        • Goff D.C.
        • Cather C.
        • Evins A.E.
        • et al.
        Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.
        J Clin Psychiatry. 2005; 66 (quiz 147, 273-184): 183-194
        • Marder S.R.
        • Essock S.M.
        • Miller A.L.
        • et al.
        Physical health monitoring of patients with schizophrenia.
        Am J Psychiatry. 2004; 161: 1334-1349
        • Lieberman J.A.
        • Merrill D.
        • Parameswaran S.
        American Psychiatric Association (APA) guidance on the use of antipsychotic drugs and cardiac sudden death.
        2009 (Accessed April 11, 2011)
        • Wheeler A.J.
        • Harrison J.
        • Mohini P.
        • Nardan J.
        • Tsai A.
        • Tsai E.
        Cardiovascular risk assessment and management in mental health clients: whose role is it anyway?.
        Community Ment Health J. 2010; 46: 531-539
        • Mukundan A.
        • Faulkner G.
        • Cohn T.
        • Remington G.
        Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
        Cochrane Database Syst Rev. 2010; 12 (CD006629)
        • Addington J.
        • El-Guebaly N.
        • Addington D.
        • Hodgins D.
        Readiness to stop smoking in schizophrenia.
        Can J Psychiatry. 1997; 42: 49-52
        • Schroeder S.A.
        A 51-year-old woman with bipolar disorder who wants to quit smoking.
        JAMA. 2009; 301: 522-531
        • Brown S.
        • Birtwistle J.
        • Roe L.
        • Thompson C.
        The unhealthy lifestyle of people with schizophrenia.
        Psychol Med. 1999; 29: 697-701
        • Cabassa L.J.
        • Ezell J.M.
        • Lewis-Fernandez R.
        Lifestyle interventions for adults with serious mental illness: a systematic literature review.
        Psychiatr Serv. 2010; 61: 774-782
        • Maayan L.
        • Vakhrusheva J.
        • Correll C.U.
        Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.
        Neuropsychopharmacology. 2010; 35: 1520-1530
        • Lambert T.J.R.
        • Newcomer J.W.
        Are the cardiometabolic complications of schizophrenia still neglected?.
        Med J Aust. 2009; 190: S39-S42
        • Regier D.A.
        • Farmer M.E.
        • Rae D.S.
        • et al.
        Comorbidity of mental disorders with alcohol and other drug abuse.
        JAMA. 1990; 264: 2511-2518
        • Batki S.L.
        • Meszaros Z.S.
        • Strutynski K.
        • et al.
        Medical comorbidity in patients with schizophrenia and alcohol dependence.
        Schizophr Res. 2009; 107: 139-146
        • Carr V.J.
        • Lewin T.J.
        • Barnard R.E.
        • et al.
        Attitudes and roles of general practitioners in the treatment of schizophrenia compared with community mental health staff and patients.
        Soc Psychiatry Psychiatr Epidemiol. 2004; 39: 78-84
        • Lester H.
        • Tritter J.Q.
        • Sorohan H.
        Patients' and health professionals' views on primary care for people with serious mental illness: focus group study.
        BMJ. 2005; 330: 1122-1127
        • Ucok A.
        • Soygur H.
        • Atakli C.
        • et al.
        The impact of antistigma education on the attitudes of general practitioners regarding schizophrenia.
        Psychiatry Clin Neurosci. 2006; 60: 439-443
        • Jones S.
        • Howard L.
        • Thornicroft G.
        ‘Diagnostic overshadowing’: worse physical health care for people with mental illness.
        Acta Psychiatr Scand. 2008; 118: 169-171
        • National Alliance on Mental Illness (NAMI)
        Schizophrenia: Public Attitudes, Personal Needs-Views from People Living with Schizophrenia, Caregivers, and the General Public.
        NAMI, Arlington, VA2008
        • Disability Rights Commission (UK)
        Equal Treatment: Closing the Gap.
        DRC, London2006
        • Druss B.G.
        • von Esenwein S.A.
        • Compton M.T.
        • Rask K.J.
        • Zhao L.
        • Parker R.M.
        A randomized trial of medical care management for community mental health settings: the Primary Care Access, Referral, and Evaluation (PCARE) study.
        Am J Psychiatry. 2010; 167: 151-159
        • Druss B.G.
        • Von Esenwein S.A.
        Improving general medical care for persons with mental and addictive disorders: systematic review.
        Gen Hosp Psychiatry. 2006; 28: 145-153
        • Collins C.
        • Levis Hewson D.
        • Munger R.
        • Wade T.
        Evolving Models of Behavioral Health Integration in Primary Care.
        Milbank Memorial Fund, New York2010